Cardiology: Clinical Research Program

Cardiology: Clinical Studies Open For Enrollment

• PROTOCOL CY 6031 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
• PROTOCOL CY 6022 AN OPEN-LABEL STUDY OF CK3773274 FOR PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM)
• Observational Study Protocol CV027-012 DELIVER INSIGHTS IN HYPERTROPHIC CARDIOMYOPATHY AND OBSERVATIONAL OUTCOMES IN REAL WORLD (DISCOVER-HCM): UNITED STATES PROSPECTIVE REGISTRY STUDY
• A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

 

PROTOCOL CY 6031 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION

Eligibility

• Symptomatic Hypertrophic cardiomyopathy
• Hemoglobin at least 10 g/dL at screening
• No moderate-severe valvular aortic stenosis and/or regurgitation

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT05186818

Principal Investigator

Dr. Srihari Naidu

Contact for Study Screening

Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org

 

PROTOCOL CY 6022 AN OPEN-LABEL STUDY OF CK3773274 FOR PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM)

Eligibility

• Symptomatic Hypertrophic cardiomyopathy
• Any acute or serious comorbid
  

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT04848506

Principal Investigator

Dr. Srihari Naidu

Contact for Study Screening

Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org

 

Observational Study Protocol CV027-012 DELIVER INSIGHTS IN HYPERTROPHIC CARDIOMYOPATHY AND OBSERVATIONAL OUTCOMES IN REAL WORLD (DISCOVER-HCM): UNITED STATES PROSPECTIVE REGISTRY STUDY

Eligibility

• Diagnosis of obstructive Hypertrophic cardiomyopathy
  

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT05489705

Principal Investigator

Dr. Srihari Naidu

Contact for Study Screening

Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org

 

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Eligibility

• Atherosclerotic Cardiovascular Disease by the history of either Myocardial infarction or Coronary revascularization.
• No severe renal dysfunction.
  

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT05581303

Principal Investigator

Dr. Diwakar Jain

Contact for Study Screening

Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org